US10780055 — Delayed release deferiprone tablets and methods of using the same
Method of Use · Assigned to Chiesi Farmaceutici SpA · Expires 2038-10-25 · 12y remaining
What this patent protects
This patent protects delayed release tablets containing deferiprone, also known as Ferriprox, for oral administration.
USPTO Abstract
The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.
Drugs covered by this patent
- Ferriprox (DEFERIPRONE) · Chiesi
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3083 |
— | Ferriprox |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.